Handbook of Clinical medicine
KEYWORDS: patient, disease, patients, history, pain, heart, symptoms, ask, time, treatment, risk, examination, aortic, iinnddbb, pulse

Score <4: do D-dimer empirically (LMWH) if delay D dimer +ve: immediate CTPA D-dimer Ωve: consider or empiral treatment LMWH alternative diagnosis Length of treatment • Provoked: 3 months and then reassess risk to benefi t profi le (depends on whether risk factor persists) • Unprovoked: treatment is usually continued for >3 months (people with no identifi able risk factor) • Malignancy: continue treatment with LMWH for 6 months or until cure of cancer • Pregnancy: LMWH is continued until delivery/end of pregnancy Fig 4.16 Investigation and management of PE. Direct oral anticoagulants (DOACS) Oral alternatives to warfarin (dabigatran, rivaroxaban, apixaban, edoxaban) have been available for treatment of PE since NICE approval in 2012. They have a rapid onset of action (without the need for LMWH overlap) and can be administered in fi xed doses without the need for continuous monitoring. Monitoring is required to assess compliance, side eff ects (eg bleeding), and presence of VTE. Antidotes for DOACS are becoming available and in the USA idarucizumab is already licensed. __OOHHCCMM__1100ee..iinnddbb 119911 0022//0055//22001177 1199::0077 enicidem tsehC 192 Pleural eff usion Defi nitions A pleural eff usion is fl uid in the pleural space. Eff usions can be divided by their
